Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Athenex, Inc.
Cash is available for start-up, growth-stage and public companies through Texas Medical Center’s newly doubled venture fund, a pandemic preparedness initiative and new VC funds. In recent financings, Nutcracker closed a $167m series C round and 2Seventy raised $170m in a private placement.
COVID does not appear to be a driving factor, and letters are split almost equally between clinical and quality concerns.
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
Following two record-breaking years for biotech fundraising, stock valuations are heading downwards. Biopharma executives and industry experts surveyed by Scrip anticipate big pharma executing more deals and acquisitions in 2022.
- Other Names / Subsidiaries
- QuaDPharma, LLC., Kinex Pharmaceuticals, Axis Therapeutics Limited
- Kuur Therapeutics, Inc.